Glycosaminoglycan Therapy for Long-Term Diabetic Complications?
Total Page:16
File Type:pdf, Size:1020Kb
Diabetologia (1998) 41: 975±979 Ó Springer-Verlag 1998 For debate Glycosaminoglycan therapy for long-term diabetic complications? G.Gambaro1, J.Skrha2, A. Ceriello3 1 Institute of Internal Medicine, Division of Nephrology, University of Padua, Italy 2 3rd Department of Internal Medicine, Charles University, Prague, Czech Republic 3 Department of Internal Medicine, University of Udine, Italy Long-term complications are the most important and an aminosugar (glucosamine or galattosamine) cause of mortality of diabetic patiens in western [5]. These molecules are widely distributed in the countries and diabetic nephropathy has emerged as body and prominent in extracellular matrices [5]. a major determinant of end-stage renal failure [1]. Three major classes of GAGs have been de- Moreover, patients with diabetes mellitus have a scribed: a predominant large chondroitin sulphate, a high probability of developing acute cardiovascular small dermatan sulphate and a polydisperse heparan disease, in particular myocardial infarction and cere- sulphate (HS) [5]. GAGs are vital in maintaining the brovascular stroke which are the cause of death in structural integrity of the tissue and studies have nearly 80% of this population [2]. Although data shown that basement membranes contain HS in the from the Diabetes Control and Complications Trial form of a proteoglycan unique to that tissue [5]. HS establish that hyperglycaemia has a central role in di- forms anionic sites in this matrix and are thought to abetic complications, strict metabolic control can be restrict the passage of proteins through the basement difficult to achieve. The search for new and ancillary membrane [5]. approaches to diabetic complications is therefore warranted and understanding the distal pathway of glucose toxicity assumes clinical and therapeutical GAG metabolism and diabetes mellitus significance. Thus, evidence has been provided [3, 4] that the alterations of the glycosaminoglycan In diabetic patients, the increased macromolecular (GAG) structure and metabolism may be of major permeability within the glomeruli that precedes the importance for the development of diabetic compli- onset of established renal lesions and the increased cations. The aim of this article is to stress the hypoth- vascular permeability to albumin seem to be related esis that GAGs might play an important role in the to structural alterations in the macromolecular path- pathogenesis of late diabetic complications and that way, i.e. the extracellular matrix, between the endo- their treatment may be useful in several of these com- thelial cells [4]. The nature of this alteration may be plications. related to the loss of negatively charged molecules of extracellular matrix and of the endothelium, among which HS is highly represented. A number of GAG structure and function reports indicate that HS metabolism is impaired in di- abetes and this is responsible for the extracellular ma- GAGs are highly glycosylated and sulphated glyco- trix negative charge loss [4]. HS is a strongly nega- proteins, consisting of dimeric repeated units con- tively charged molecule that is structurally similar to taining an uronic acid (iduronic or glucuronic acid) heparin but its base polymer has a lower degree of processing (sulphation, epimerization) (Fig.1). The HS chain imparts a negative charge to the basement Corresponding author: Dr A. Ceriello, Chair of Internal Medi- membrane and determines the molecular charge cine, University of Udine, P.le S.Maria della Misericordia, 33100 Udine, Italy permselectivity of the glomerular basement mem- Abbreviations: GAGs, Glycosaminoglycans; GF, growth fac- brane [4]. The reduction in HS negative charges may tors; HS, heparan sulphate; HS-PG, heparan sulphate-pro- depend on either a decreased sulphation of the gly- teoglycan; t-PA, tissue plasminogen activator. cosaminoglycan molecule or an absolute reduction 976 G.Gambaro et al.: GAG therapy for diabetes - CH2OR' CH2OSO3 CH2OH O O - O O3SO COO- OH OH O - O O O O O COO COO- OH OH - NHR OH NHSO3 O NHCOCH3 O O OH - OH n OSO3 n n - R – – COOH3, – SO3 , - R' – – H – SO3 Heparan sulphate Heparin Dermatan sulphate Fig.1. Chemical structures of heparan sulphate, heparin and in the pathogenesis of diabetic nephropathy [9]. Fi- dermatan sulphate nally, it has recently been suggested that oxidative stress is involved in the pathogenesis of diabetic com- plications [10]. Further mesangial cells subjected to oxidative stress have been shown to selectively re- in the heparan sulphate-proteoglycan (HS-PG). It duce HS synthesis [11]. has been suggested that the first HS-PG change in di- abetes might be an undersulphation of HS, followed by an absolute, or most likely a relative decrease in GAG treatment of diabetic nephropathy HS [6]. The treatment of diabetic nephropathy with GAGs was originally proposed on the basis of the some- Abnormal GAGs and diabetic nephropathy what simple idea that restoring the lacking anionic charges and GAGs to the diabetic kidney could The altered GAG metabolism in the diabetic kidney, cure the albuminuria and putatively return the above and the abnormal GAG and extracellular matrix described cell functional anomalies to normal [12] composition of the glomerular basement membrane (Fig.2). The observation of pathophysiological simi- may be important determinants of diabetic nephrop- larities between diabetic nephropathy and the so- athy, glomerulosclerosis, and renal failure due to the called ªremnant kidneyº, i.e. reduced functioning abnormal glomerular permselectivity to proteins and tissue after a renal lesion [13], was also considered. albuminuria. Data support the hypothesis that in- In the classical model reproducing this kind of le- creased glomerular trafficking of proteins has detri- sion, the 5/6 subtotal nephrectomized rat, heparin mental effects on nephropathies, and in many prima- and derived drugs were shown to be effective in ry glomerulopathies, proteinuria is certainly a risk slowing down the progression to uraemia [14]. In factor for the development of glomerulosclerosis and view of these considerations, the effect of heparin renal failure [7]. However, the altered GAG or PG and GAGs on diabetic nephropathy was studied in composition or both may be an important factor in the streptozotocin diabetic model. This approach re- the determination and the progression of diabetic duced glomerular basement membrane thickening nephropathy not only because of the abnormal glo- [12] and anionic charge loss [12], as well as mesangial merular basement membrane. The qualitative and area expansion [15], and prevented the onset of albu- quantitative changes in the PG composition of the re- minuria [12, 16] and the disorder in charge permse- nal extracellular matrix could also deeply affect the lectivity [16]. Marshall et al. [15], however, were not growth and synthetic behaviour of renal endothelial, able to confirm a reduction of albumin excretion in mesangial, and glomerular and tubular epithelial female streptozotocin diabetic Wistar rats on a twice cells, thus inducing glomerulosclerosis; indeed, the daily dose of 200 units heparin over a period of cell/extracellular matrix interaction plays an impor- 6 months. They did, though, report that basement tant role in regulating the adhesion, migration and membrane thickness, mesangial volume fraction and proliferation of these cells [8]. Moreover, extracellu- absolute mesangial volume were lower in heparin- lar matrix and cell-associated PGs may modulate the treated diabetic animals compared with untreated activity of growth factors. In particular, it was sug- diabetic animals [15]. Recently these discrepancies gested that the cell surface and extracellular matrix have been discussed extensively [17]. The difference HS-PG may act together to regulate the bioavailabil- in the results may be mainly due to different quali- ity of otherwise diffusible effector molecules to their ties and quantities of drugs in the different protocols signal transducting receptor [8]. Note that a huge [17]. number of growth factors and cytokines are associat- Heparin and related drugs have no effect on the ed with HS-PGs and many are, or may be, involved metabolic control of diabetes. Since heparin and G.Gambaro et al.: GAG therapy for diabetes 977 Normal filtration Filtration in diabetic nephropathy Filtration after GAG therapy Albumin (-) Albumin (-) Albumin (-) (-) (-) (-) (-) (-) (-) (-) (-) Albumin (-) Albumin (-) Albumin (-) (-) (-) (-) (-) (-) Hypo sulphated Pore (-) (-) (-) Pore (-) (-) Pore GAGs (-) (-) Sulphated (-) Reduced (-) Sulphated (-) (-) GAGs (-) synthesis (-) (-) GAGs (-) (-) (-) (-) (-) of GAGs (-) Normoalbuminuria Albuminuria Reduced excretion of albumin Restoration of Improvement of - GBM width - GAG sulphation - anionic GBM charges - GBM permeability Down regulation of - TGFβ - Collagen IV deposition Fig.2. Hypothetical mechanisms leading to albuminuria in di- nase-C-dependent activation of the TGF-b1 gene in abetic patients and to curative effects of glycosaminoglycans. mesangial cells in vitro [20]. The glycosaminoglycan-dependent negative charge of the In the light of these findings, studies were con- basement membrane determines the permselectivity of glo- meruli to albumin. In diabetes a loss of glycosaminoglycans fa- ducted in diabetic patients. Recent reports described vours albumin excretion. The administration of glycosamino- favourable results on proteinuria in diabetic ne- glycans restores the negative charge of basement membrane, phropathy following